Success Metrics

Clinical Success Rate
78.7%

Based on 37 completed trials

Completion Rate
79%(37/47)
Active Trials
4(6%)
Results Posted
41%(15 trials)
Terminated
10(14%)

Phase Distribution

Ph early_phase_1
1
1%
Ph phase_4
4
6%
Ph not_applicable
10
14%
Ph phase_2
33
46%
Ph phase_3
2
3%
Ph phase_1
20
28%

Phase Distribution

21

Early Stage

33

Mid Stage

6

Late Stage

Phase Distribution70 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
20(28.6%)
Phase 2Efficacy & side effects
33(47.1%)
Phase 3Large-scale testing
2(2.9%)
Phase 4Post-market surveillance
4(5.7%)
N/ANon-phased studies
10(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.0%

37 of 50 finished

Non-Completion Rate

26.0%

13 ended early

Currently Active

4

trials recruiting

Total Trials

72

all time

Status Distribution
Active(4)
Completed(37)
Terminated(13)
Other(18)

Detailed Status

Completed37
unknown18
Terminated10
Withdrawn3
Recruiting2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
72
Active
4
Success Rate
78.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.4%)
Phase 120 (28.6%)
Phase 233 (47.1%)
Phase 32 (2.9%)
Phase 44 (5.7%)
N/A10 (14.3%)

Trials by Status

completed3751%
recruiting23%
terminated1014%
unknown1825%
withdrawn34%
active_not_recruiting23%

Recent Activity

Clinical Trials (72)

Showing 20 of 72 trialsScroll for more
NCT01652092Not Applicable

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active Not Recruiting
NCT02171104Phase 2

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Active Not Recruiting
NCT02881086Phase 3

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed
NCT05827549Phase 2

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

Recruiting
NCT03755414Phase 1

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Completed
NCT06752720Phase 2

Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients

Recruiting
NCT04080921Phase 1

Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis

Completed
NCT04062136Phase 1

Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia

Completed
NCT01041508Phase 1

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

Completed
NCT00199056Phase 4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Completed
NCT00199069Phase 4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)

Completed
NCT03263767Phase 2

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Terminated
NCT00051311Phase 2

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed
NCT04886947Not Applicable

Alveolar Cleft Reconstruction Powered by

Unknown
NCT00442130Phase 1

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Completed
NCT02323477Phase 1

Human Umbilical Cord Stroma MSC in Myocardial Infarction

Terminated
NCT00303719Phase 2

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Terminated
NCT01490723Phase 2

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Completed
NCT00566696Phase 2

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Completed
NCT01010217Phase 2

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
72